1. Nicolescu AC, Ionescu MA, Constantin MM, Ancuta I, Ionescu S, Niculet E, Tatu AL, Zirpel H, Thaçi D (2022) Psoriasis Management challenges regarding difficult-to-treat areas: therapeutic decision and effectiveness. Life (Basel) 12(12):2050
2. Orsini D, Gargiulo L, Ibba L, Ingurgio RC, Valenti M, Perugini C, Pacifico A, Maramao FS, Frascione P, Costanzo A et al (2023) Effectiveness of risankizumab in plaque psoriasis with involvement of difficult-to-treat areas: a real-world experience from two referral centers. J Dermatolog Treat 34:2220849
3. Gisondi P, Fargnoli MC, Amerio P, Argenziano G, Bardazzi F, Bianchi L, Chiricozzi A, Conti A, Corazza M, Costanzo A et al (2022) Italian adaptation of EuroGuiDerm guideline on the systemic treatment of chronic plaque psoriasis. Ital J Dermatol Venerol 157(Suppl S1):1–78 [CrossRef] [PubMed]
4. Manzo Margiotta F, Michelucci A, Capalbo E, Ricceri F, Rosi E, Rossari S, Magnano M, Savarese I, Milanesi N, Simoni B, Romanelli M, Rubegni P, Cesare DI, Panduri A, Pescitelli S, Trovato L, Prignano E (2024) Efficacy of risankizumab after intra-class switching between anti IL-23 antagonists: a multi-center, retrospective, real-life observation. Ital J Dermatol Venerol 159(1):64–65
5. Vaiopoulos AG, Dalamaga M, Katsimbri P, Koumourtzis M, Lampadaki K, Theodoropoulos K, Theotokoglou S, Kanelleas A, Syrmali A, Filippopoulou A, Zoupidou K, Katoulis A, Papadavid E (2023) Real-world data show high efficacy of IL23 inhibitors guselkumab and risankizumab in psoriatic arthritis and difficult-to-treat areas. Int J Dermatol 62(11):1404–1413